Shire Licenses Sangamo’s Genome-Editing Technology for Haemophilia and Other Monogenic Diseases
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 2 (Table of Contents)
Published: 20 Feb-2012
DOI: 10.3833/pdr.v2012.i2.1687 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Shire has agreed to pay Sangamo BioSciences US$13 M upfront for the global rights to use the company’s zinc finger DNA-binding protein (ZFP) technology platform to develop therapies for haemophilia and other monogenic diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS